The generic drug segment was hot in 2015, but investor interest has cooled considerably in 2017. Here’s a look at the recent M&A activity.
Way back in February 2015, Pfizer Inc. (NYSE: PFE) agreed to pay $17 billion to acquire Hospira, Inc., a global provider of injectable drugs and infusion technologies. In early October 2016, Pfizer agreed to sell Hospira’s infusion therapy business to ICU Medical Inc. (NASDAQ: ICUI) for $1 billion in cash and stock. The company develops, manufactures and sells […]
August is a busy month for Premier, Inc. (NASDAQ: PINC), which bills itself as a healthcare improvement company, with an alliance of 3,400 hospitals and 110,000 other providers. In the first two weeks of August 2015, the company has announced two acquisitions totaling $465 million. The first deal, for CECity, Inc. was announced on August […]
Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.